利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.02 秒)

    Attenuation of fibroblast proliferation
    1.
    发明授权
    Attenuation of fibroblast proliferation 失效
    成纤维细胞增殖的衰减

    公开(公告)号：US07056711B2

    公开(公告)日：2006-06-06

    申请号：US09727873

    申请日：2000-12-01

    申请人： Elizabeth M. Denholm ,  Elizabeth Cauchon ,  Paul J. Silver

    发明人： Elizabeth M. Denholm ,  Elizabeth Cauchon ,  Paul J. Silver

    IPC分类号： C12N9/00

    CPC分类号： A61K38/51 ,  C12Y402/02019

    摘要： Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B(dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.

    摘要翻译： 高纯度和特异性的糖胺聚糖降解酶，软骨素酶B和软骨素酶AC用于治疗纤维增生性疾病。 从细胞表面去除硫酸软骨素B（硫酸皮肤素），并且在较小程度上去除硫酸软骨素A或C有效地降低细胞上的生长因子受体，从而降低对这种生长因子的细胞增殖反应。 此外，去除硫酸软骨素减少胶原蛋白的分泌，胶原蛋白是主要的细胞外基质成分之一。 通过组合抑制成纤维细胞增殖和胶原合成，用软骨素酶B或软骨素酶AC治疗可以减少牛皮癣，硬皮病，瘢痕疙瘩，肺纤维化和手术粘连中发现的纤维组织的大小。

    Use of heparinases to decrease inflammatory response
    2.
    发明授权
    Use of heparinases to decrease inflammatory response 失效
    使用肝素降低炎症反应

    公开(公告)号：US07264799B2

    公开(公告)日：2007-09-04

    申请号：US11357967

    申请日：2006-02-22

    申请人： D. Clark Bennett ,  Elizabeth Cauchon ,  Dominique Fink ,  Brigette Grouix ,  Ariane Hsia ,  Pamela Danagher ,  Joseph F. Zimmermann

    发明人： D. Clark Bennett ,  Elizabeth Cauchon ,  Dominique Fink ,  Brigette Grouix ,  Ariane Hsia ,  Pamela Danagher ,  Joseph F. Zimmermann

    IPC分类号： A61K38/51 ,  C12N9/88

    CPC分类号： A61K38/51 ,  A61K47/50 ,  C07K2319/00 ,  C12N9/88 ,  Y10S424/81

    摘要： Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

    摘要翻译： 肝素酶可用作治疗局部炎症反应的药物治疗。 用肝素酶处理激活的内皮抑制白细胞滚动，粘连和外渗。 内皮细胞表面和基底膜中的大部分肝素和硫酸乙酰肝素通过暴露于肝素酶而降解。 此外，通过肝素酶消化可溶解附着于活化内皮上的肝素/硫酸乙酰肝素的固定化趋化因子。 肝素酶可以输注到血管系统中，以抑制发炎组织中白细胞的积累，并减少由局部炎症引起的损伤。 肝素酶对活化内皮的靶向可以通过局部施用和/或使用含有内皮配体结合结构域的转基因肝素酶来实现。

    Use of heparinases to decrease inflammatory response
    3.
    发明申请
    Use of heparinases to decrease inflammatory response 失效
    使用肝素降低炎症反应

    公开(公告)号：US20060140928A1

    公开(公告)日：2006-06-29

    申请号：US11357967

    申请日：2006-02-22

    申请人： D. Bennett ,  Elizabeth Cauchon ,  Dominique Fink ,  Brigette Grouix ,  Ariane Hsia ,  Pamela Danagher ,  Joseph Zimmermann

    发明人： D. Bennett ,  Elizabeth Cauchon ,  Dominique Fink ,  Brigette Grouix ,  Ariane Hsia ,  Pamela Danagher ,  Joseph Zimmermann

    IPC分类号： A61K38/47

    CPC分类号： A61K38/51 ,  A61K47/50 ,  C07K2319/00 ,  C12N9/88 ,  Y10S424/81

    摘要： Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

    摘要翻译： 肝素酶可用作治疗局部炎症反应的药物治疗。 用肝素酶处理激活的内皮抑制白细胞滚动，粘连和外渗。 内皮细胞表面和基底膜中的大部分肝素和硫酸乙酰肝素通过暴露于肝素酶而降解。 此外，通过肝素酶消化可溶解附着于活化内皮上的肝素/硫酸乙酰肝素的固定化趋化因子。 肝素酶可以输注到血管系统中，以抑制发炎组织中白细胞的积累，并减少由局部炎症引起的损伤。 肝素酶对活化内皮的靶向可以通过局部施用和/或使用含有内皮配体结合结构域的转基因肝素酶来实现。